Offering expands on the company’s cryoablation suite of products by
introducing an even more flexible probe for use in a variety of surgical
interventions to treat cardiac arrhythmias
WEST CHESTER, Ohio--(BUSINESS WIRE)--Sep. 30, 2015--
ATRC), a leading innovator in treatments for atrial fibrillation
(Afib) and left atrial appendage management, today announced the launch
of the cryoFORM™ cryoablation probe, which offers increased probe
flexibility to adapt to a variety of surgical ablation procedures. This
offering adds to the cryoICE™ family of ablation products which are used
in the cryosurgical treatment of cardiac arrhythmias.
The cryoFORM™ probe builds off of the company’s core strengths in
cryoablation technology, leveraging such important features as thermal
capacity to remove heat and active defrost, which allows the probe to be
safely and quickly detached while maintaining the tissue’s frozen state.
Building upon those strengths, the new probe offers increased
flexibility, allowing the surgeon to more easily manipulate and apply
the device and conform to challenging anatomies.
“We are excited to announce the launch of the cryoFORM™ probe,” said
Mike Carrel, President and CEO of AtriCure. “This builds off of one of
our company’s core competencies in cryoablation, and offers our
customers another option when performing surgical ablation by allowing
for easier manipulation and application of the device. We have listened
to our customers’ requests for a significantly more flexible probe that
doesn’t compromise on the core strengths and features they value most.”
The development of the cryoFORM™ probe is also intended to address the
trend towards more minimally invasive techniques in cardiac surgery,
which are being used in conjunction with a variety of cardiac therapies,
including mitral and aortic valve repair. In addition to an even more
malleable probe shaft, the cryogen supply tubing for the cryoFORM™ probe
has been made more flexible to allow for easier handling and delivery,
which improves the overall ease-of-use in settings where range of motion
Cryoablation technology has been used for decades in the treatment of
cardiac arrhythmias, and has advantages over other energy sources for
creating lesions on certain cardiac structures. The entire cryoICE™
system offers exceptional cryo ablation performance by leveraging
nitrous oxide, which is the most widely used and published cryogen in
all cardiac specialties. Nitrous oxide combined with the unique design
of the probe ensures rapid extraction of heat from targeted tissue, one
of the primary determinants of success in cryo ablation. This rapid heat
extraction combine with a slow and natural thawing process called active
defrost, provides maximum cell death of targeted tissues.
“The cryoFORM probe works well in MI-MVR procedures and allows me to
easily shape and position the probe inside the LA using endoscopic
instruments,” said Nicolas Doll, MD, and Professor at Sana Herzchirugie
in Stuttgart, Germany. “The probe is a great addition to the cryoICE
family that I can rely on for fully transmural lesions.”
The cryoFORM™ probe has received CE mark and is pending FDA clearance.
AtriCure, Inc. is a medical device company providing innovative atrial
fibrillation (Afib) solutions designed to produce superior outcomes that
reduce the economic and social burden of atrial fibrillation. AtriCure’s
Synergy™ Ablation System is the first and only surgical device approved
for the treatment of persistent and longstanding persistent forms of
Afib in patients undergoing certain open concomitant procedures.
AtriCure’s AtriClip™ left atrial appendage management (LAAM) exclusion
device is the most widely sold device worldwide that’s indicated for the
occlusion of the left atrial appendage. The company believes
cardiothoracic surgeons are adopting its ablation and LAAM devices for
the treatment of Afib and reduction of Afib related complications such
as stroke. Afib affects more than 33 million people worldwide. For more
information visit AtriCure.com or follow us on Twitter @AtriCure.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150930005252/en/
Source: AtriCure, Inc.
Valerie Storch-Willhaus, 612-605-3311
Director, Corporate Marketing and Communications
Senior Vice President
and Chief Financial Officer